Page last updated: 2024-11-04

alachlor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alachlor : An aromatic amide that is N-(2,6-diethylphenyl)acetamide substituted by a methoxymethyl group at at the nitrogen atom while one of the hydrogens of the methyl group has been replaced by a chlorine atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2078
CHEMBL ID1414154
CHEBI ID2533
SCHEMBL ID15501
MeSH IDM0040217

Synonyms (119)

Synonym
BIDD:PXR0027
BIDD:ER0383
alapaz
BRD-K02548315-001-02-7
2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide
CHEBI:2533 ,
alachlore
chloressigsaeure-n-(methoxymethyl)-2,6-diaethylanilid
2-chloro-2',6'-diethyl-n-(methoxymethyl)acetanilide
KBIO1_001510
DIVK1C_006566
2-chloro-n-(2,6-diethylphenyl)-n-[(methyloxy)methyl]acetamide
SPECTRUM_001859
acetamide, 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)-
SPECTRUM5_001984
NCGC00090758-01
brn 2944476
lasagrin
pillarzo
alachlor technical
ccris 3155
acetanilide, 2-chloro-2',6'-diethyl-n-(methoxymethyl)-
lasso
einecs 240-110-8
chimiclor
lazo
lasso micro-tech
alachlor technical (90% or more)
2-chloro-n-(2,6-diethyl)phenyl-n-methoxymethylacetamide
alochlor
hsdb 1014
alpha-chloro-2',6'-diethyl-n-methoxymethylacetanilide
alatox 480
alanex
metachlor
cp 50144
n-(methoxymethyl)-2,6-diethylchloroacetanilide
chloressigsaeure-n-(methoxymethyl)-2,6-diaethylanilid [german]
epa pesticide chemical code 090501
caswell no. 011
methachlor
alanox
ai3-51506
alachlor [ansi:bsi:iso]
alachlore [iso-french]
alachlor
15972-60-8
BSPBIO_002389
NCGC00090758-02
NCGC00090758-04
NCGC00090758-03
KBIO2_007508
KBIO3_001889
KBIOGR_001109
KBIO2_004940
KBIOSS_002376
KBIO2_002372
SPECPLUS_000470
SPECTRUM4_000675
SPECTRUM3_000835
SPECTRUM2_001853
SPBIO_001666
SPECTRUM330043
NCGC00090758-05
NCGC00090758-06
MLS002695955
smr000777860
phenmetrazine-d5 hydrochloride
FT-0661447
FT-0657940
xcsgpavhzfqhge-uhfffaoysa-
inchi=1/c14h20clno2/c1-4-11-7-6-8-12(5-2)14(11)16(10-18-3)13(17)9-15/h6-8h,4-5,9-10h2,1-3h3
NCGC00090758-08
NCGC00090758-07
NCGC00090758-09
HMS3091A18
24s2s61pxl ,
unii-24s2s61pxl
NCGC00259754-01
tox21_202205
dtxsid1022265 ,
cas-15972-60-8
dtxcid402265
tox21_300713
NCGC00254619-01
CCG-39391
2-chloro-2',6'-diethyl-n-methoxymethylacetanilide
satochlor
2',6'-diethyl-n-(methoxymethyl)-2-chloroacetanilide
nitala
AKOS015889908
CHEMBL1414154
SCHEMBL15501
alachlor [hsdb]
alachlor [mi]
alachlor [iso]
n-methoxymethyl-n-(2,6-diethylphenyl)chloroacetamide
2-chloro-2',6'-diethyl-n-(methoxymethyl) acetanilide
2-chloro-2', 6'-diethyl-n-(methoxymethyl)acetanilide
2-chloro-n-(methoxymethyl)-n-(2,6-diethyl-phenyl)-acetamide
alachlor, pestanal(r), analytical standard
alachlor 100 microg/ml in methanol
alagan
2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide, 9ci
2-chloro-2',6'-diethyl-n-(methoxymethyl)-acetanilide
ralchlor
2-chloro-2',6'-diethyl-n-(methoxymethyl)-acetanilde
alachlor-atrazine
n-(methoxymethyl)-2-chloro-n-(2,6-diethylphenyl)acetamide
J-009637
1246817-91-3
alachlor, certified reference material, tracecert(r)
alachlor 10 microg/ml in acetone
Q421204
alachlor 5000 microg/ml in methanol
alachlor 1000 microg/ml in acetone
53 - eqsd directive - low level triazines
34c - wfd c
108 - eqsd directive - low level triazines

Research Excerpts

Overview

Alachlor is a widely used pre-emergent chloroacetanilide herbicide. Alachlor has been shown to have many harmful ecological and environmental effects. It is associated with cancer of the nasal cavity, thyroid, and stomach in rats.

ExcerptReferenceRelevance
"Alachlor is an herbicide that is widely used worldwide to protect plant crops against broadleaf weeds and annual grasses. "( Mechanism study of alachlor biodegradation by Paecilomyces marquandii with proteomic and metabolomic methods.
Długoński, J; Soboń, A; Szewczyk, R; Słaba, M, 2015
)
2.19
"Alachlor is a widely used pre-emergent chloroacetanilide herbicide which has been shown to have many harmful ecological and environmental effects. "( Cu/Zn-superoxide dismutase and glutathione are involved in response to oxidative stress induced by protein denaturing effect of alachlor in Saccharomyces cerevisiae.
Auesukaree, C; Kerdsomboon, K; Rattanawong, K, 2015
)
2.07
"Alachlor is an herbicide used primarily in the production of corn (maize), peanuts, and soybeans and is associated with cancer of the nasal cavity, thyroid, and stomach in rats. "( Progression of alachlor-induced olfactory mucosal tumours.
Bolon, B; Burman, DM; Genter, MB, 2002
)
2.11
"Alachlor proved to be a good chemical probe for examining indirect photolysis due to its lack of reactivity by either direct photolysis or dark reaction pathways and its ubiquity as an agricultural herbicide."( Indirect photolysis promoted by natural and engineered wetland water constituents: processes leading to alachlor degradation.
Chin, YP; Miller, PL, 2005
)
1.26
"Alachlor is a widely used herbicide for which there is significant human exposure, principally through groundwater contamination and inhalation. "( An evaluation of the feasibility of using cytogenetic damage as a biomarker for alachlor exposure.
Erexson, GL; Kligerman, AD, 1999
)
1.97
"Alachlor is a preemergence herbicide."( In vivo percutaneous absorption and skin decontamination of alachlor in rhesus monkey.
Maibach, HI; Melendres, J; Wester, RC, 1992
)
1.25

Effects

Alachlor has been widely used in agriculture all over the world. Alachlor, which has demonstrated thyroid effects in mammals, may be largely responsible.

ExcerptReferenceRelevance
"Alachlor has been a commonly applied herbicide and is a substance of ecotoxicological concern. "( Transcriptional profiling in Saccharomyces cerevisiae relevant for predicting alachlor mechanisms of toxicity.
Becker, JD; Gil, FN; Gonçalves, AC; Jacinto, MJ; Viegas, CA, 2011
)
2.04
"Alachlor, which has demonstrated thyroid effects in mammals, may be largely responsible for the observed effects."( Thyroid disruption in the lizard Podarcis bocagei exposed to a mixture of herbicides: a field study.
Amaral, MJ; Bicho, RC; Carretero, MA; Faustino, AM; Mann, RM; Power, DM; Rêma, A; Soares, AM, 2013
)
1.11
"Alachlor has been widely used in agriculture all over the world. "( Effects of long-term alachlor exposure on hepatic antioxidant defense and detoxifying enzyme activities in crucian carp (Carassius auratus).
Ding, H; Jiang, W; Liu, H; Lu, Y; Yi, X; Zhang, M, 2007
)
2.1

Treatment

Alachlor-treated A/J mice developed pronounced intracellular accumulation of amorphous eosinophilic material in the olfactory mucosa. Alachlor solution treated by ferrate for 10 min inhibited an up-flow biotreatment with activated sludge.

ExcerptReferenceRelevance
"Alachlor-treated A/J mice developed pronounced intracellular accumulation of amorphous eosinophilic material in the olfactory mucosa, foci of respiratory-like metaplasia,and hyperplasia of nasal mucus glands."( Strain-specific of alachlor on murine olfactory mucosal responses.
Genter, MB; Goss, KH; Groden, J,
)
1.18
"Alachlor solution treated by ferrate for 10 min inhibited an up-flow biotreatment with activated sludge."( Improving alachlor biodegradability by ferrate oxidation.
Liu, Y; Yan, XL; Zhang, B; Zhu, JH, 2006
)
1.46

Toxicity

Alachlor and acetochlor are hepatotoxicity in rats and dogs. Atrazine and alachlor were observed to not be acutely toxic to bees. Estrogen receptor positive (ER+) MCF-7 human mammary carcinoma was treated with ala.

ExcerptReferenceRelevance
" Alachlor was least toxic of the three pesticides tested."( Toxicity assessment of atrazine, alachlor, and carbofuran and their respective environmental metabolites using Microtox.
Kross, BC; Raue, LE; Vergara, A, 1992
)
1.48
" Estrogen receptor positive (ER+) MCF-7 human mammary carcinoma, HepG2 (ER+) human hepatocellular carcinoma and VERO estrogen receptor negative (ER-) non-transformed monkey fibroblast cell lines were treated with alachlor and acetochlor (2-500 microg/ml) as toxic agents, and RESV (10 microM) as preventive agent."( Chemopreventive properties of trans-resveratrol against the cytotoxicity of chloroacetanilide herbicides in vitro.
Jakab, MG; Kocsis, Z; Marcsek, ZL; Szende, B; Tompa, A, 2005
)
0.51
" In agreement, CDEPA was less toxic than parent alachlor."( Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7.
Meyer, SA; Miranda, SR, 2007
)
0.86
" Alachlor exerted a toxic effect on the two nontarget cells used."( Assessment of the potential toxicity of herbicides and their degradation products to nontarget cells using two microorganisms, the bacteria Vibrio fischeri and the ciliate Tetrahymena pyriformis.
Bohatier, J; Bonnemoy, F; Bonnet, JL; Dusser, M, 2007
)
1.25
"Noncancerous adverse effects observed at the lowest dose for chloroacetanilide herbicides alachlor [2-chloro-2',6'-diethyl-N-(methoxymethyl)-acetanilide] and acetochlor [2-chloro-2'-methyl-6'-ethyl-N-(ethoxymethyl)acetanilide], but not metolachlor [2-chloro-2'-ethyl-6'-methyl-N-(1-methyl-2-methoxymethyl)acetanilide], are hepatotoxicity in rats and dogs."( Comparative cytotoxicity of alachlor, acetochlor, and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes.
Kale, VM; Meyer, SA; Miranda, SR; Wilbanks, MS, 2008
)
0.86
" In fact, although pesticides were not detected in elutriates, high levels of un-ionized ammonia were recorded, which is considered highly toxic to aquatic life."( A whole sample toxicity assessment to evaluate the sub-lethal toxicity of water and sediment elutriates from a lake exposed to diffuse pollution.
Abrantes, N; de Figueiredo, DR; Gonçalves, F; Marques, CR; Pereira, MJ; Pereira, R, 2009
)
0.35
" These findings indicate that, in vitro, higher doses of saquinavir have adverse effects on sperm motility, mitochondrial potential and acrosome reaction."( In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete.
Ahmad, G; Bujan, L; Daudin, M; Gandia, P; Jouanolou, V; Moinard, N, 2011
)
0.37
" The biological relevance of these results is discussed in relation to new insights into the potential adverse effects of alachlor in health of organisms from ecosystems, particularly in worst-case situations such as accidental spills or careless storage, usage, and disposal."( Transcriptional profiling in Saccharomyces cerevisiae relevant for predicting alachlor mechanisms of toxicity.
Becker, JD; Gil, FN; Gonçalves, AC; Jacinto, MJ; Viegas, CA, 2011
)
0.8
" Atrazine and alachlor were observed to not be acutely toxic to bees at doses up to 10 and 4 μg per bee, respectively."( Acute toxicity of atrazine, alachlor, and chlorpyrifos mixtures to honey bees.
Anderson, TD; Fellows, CJ; Swale, DR, 2022
)
1.38

Bioavailability

Common carp (Cyprinus carpio) were treated in aquatic mesocosms with a single pulse of the herbicides atrazine or alachlor. Liver vitellogenin gene expression in male fish for estrogenic activity, liver cytochrome P4501A1 gene expression, and DNA damage in blood cells using the single-cell gel electrophoresis method. These studies demonstrated that ESA was poorly absorbed and underwent minor metabolism.

ExcerptReferenceRelevance
" Sorption in soils and sediments is an important factor controlling the migration and bioavailability of these herbicides, while microbial degradation is the most important factor in determining their overall fate in the environment."( Biodegradation of the acetanilide herbicides alachlor, metolachlor, and propachlor.
Stamper, DM; Tuovinen, OH, 1998
)
0.56
" These studies demonstrated that ESA was poorly absorbed and underwent minor metabolism, which contrasted with the significant absorption and substantial metabolism observed with alachlor."( Ethane sulfonate metabolite of alachlor: assessment of oncogenic potential based on metabolic and mechanistic considerations.
Heydens, WF; Hopkins, WE; Hotz, KJ; Kraus, LJ; Wilson, AG, 2000
)
0.79
"Common carp (Cyprinus carpio) were treated in aquatic mesocosms with a single pulse of the herbicides atrazine or alachlor to study the bioavailability and biological activity of these herbicides using molecular indicators: Liver vitellogenin gene expression in male fish for estrogenic activity, liver cytochrome P4501A1 gene expression, and DNA damage in blood cells using the single-cell gel electrophoresis method."( Responses of molecular indicators of exposure in mesocosms: common carp (Cyprinus carpio) exposed to the herbicides alachlor and atrazine.
Campbell, S; Chang, LW; deNoyelles, FJ; Gordon, DA; Graham, DW; Knapp, CW; Lattier, DL; Meier, JR; Toth, GP, 2005
)
0.75
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
" Pine and oak wood increase the immobilization of the pesticides studied, but they also limit their bioavailability in soil by decreasing their degradation rate in amended soil."( Influence of pine or oak wood on the degradation of alachlor and metalaxyl in soil.
Azejjel, H; Marín-Benito, JM; Ordax, JM; Rodríguez-Cruz, MS; Sánchez-Martín, MJ, 2012
)
0.63
"An extensive four-year research program has been carried out to explore and acquire knowledge about the fundamental agricultural practices and processes affecting the mobility and bioavailability of pesticides in soils under semi-arid Mediterranean conditions."( Leaching of Br-, metolachlor, alachlor, atrazine, deethylatrazine and deisopropylatrazine in clayey vadoze zone: a field scale experiment in north-east Greece.
Papadakis, EN; Papadopoulou-Mourkidou, E; Vryzas, Z, 2012
)
0.67
" Adding these materials to soil requires understanding the process of pesticide sorption-desorption by wood-soils, as sorption capacity could increase, with changes in pesticide bioavailability and final fate."( Study of processes influencing bioavailability of pesticides in wood-soil systems: Effect of different factors.
Arienzo, M; Herrero-Hernández, E; Marín-Benito, JM; Rodríguez-Cruz, MS; Sánchez-Martín, MJ, 2017
)
0.46

Dosage Studied

Ofurace, oxadixyl, and alachlor were studied for their effect on hepatic xenobiotic biotransformation in male rats by dosing i.We used a ultrasound/Fe(2+)/H2O2 process in continuous dosing mode to degrade theAlachlor.

ExcerptRelevanceReference
" Assays of incurred samples were performed after dosing a cow and several chickens with alachlor."( Evaluation of commercial immunoassays for the detection of alachlor in milk, eggs and liver.
Lehotay, SJ; Miller, RW, 1994
)
0.75
" An optimum H(2)O(2) dosage was determined."( Reactor model development: the removal performance of ferrous-catalysed photo-oxidation process by examining the reaction parameters.
Chan, KH; Chu, W, 2009
)
0.35
"We used a ultrasound/Fe(2+)/H2O2 process in continuous dosing mode to degrade the alachlor."( Decontamination of alachlor herbicide wastewater by a continuous dosing mode ultrasound/Fe(2+)/H2O2 process.
Liu, C; Wang, C, 2014
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
herbicideA substance used to destroy plant pests.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
Nrf2Homo sapiens (human)Potency35.48130.09208.222223.1093AID624171
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency49.65990.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency23.26260.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency19.00950.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency38.17670.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency49.47430.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.32190.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency7.44610.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.43640.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.22750.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency30.81110.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.33820.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency37.64600.375827.485161.6524AID588526; AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency9.27300.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency43.79580.000229.305416,493.5996AID1259244; AID1259248; AID588514; AID743069; AID743078; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency34.68620.001024.504861.6448AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency30.02860.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency38.91400.023723.228263.5986AID588541; AID743223; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency56.92260.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency59.05050.001628.015177.1139AID1224843; AID1224895; AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency122.70900.039147.5451146.8240AID1224845
Caspase-7Cricetulus griseus (Chinese hamster)Potency11.80130.006723.496068.5896AID1346980
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency39.81070.316212.443531.6228AID902
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
caspase-3Cricetulus griseus (Chinese hamster)Potency11.80130.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency59.70550.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.46360.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency20.00960.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.05620.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency67.47670.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.05620.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1090127Inhibition of Arbidopsis thaliana C-terminal His-tagged KCS2 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1090125Inhibition of Arbidopsis thaliana C-terminal His-tagged At1g04220 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1100793Binding affinity to SafBP receptor in Zea mays (maize) seedlings by [3H]Saf(R-29148) binding assay2000Journal of agricultural and food chemistry, Mar, Volume: 48, Issue:3
Comparative three-dimensional quantitative structure-activity relationship study of safeners and herbicides.
AID1090128Inhibition of Arbidopsis thaliana C-terminal His-tagged KCS1 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1090123Herbicidal activity against Arabidopsis thaliana assessed as apperance of fiddle head phenotype2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1090129Inhibition of Arbidopsis thaliana C-terminal His-tagged FAE1 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1090119Inhibition of Saccharomyces cerevisiae INVSc1 ELO at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1090126Inhibition of Arbidopsis thaliana C-terminal His-tagged CER60 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1090120Growth inhibition of Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID1090124Inhibition of Arbidopsis thaliana C-terminal His-tagged At5g43760 expressed in Saccharomyces cerevisiae INVSc1 at 100 uM after 18 to 20 hr by GC/MS analysis2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Specific and differential inhibition of very-long-chain fatty acid elongases from Arabidopsis thaliana by different herbicides.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (329)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (7.90)18.7374
1990's75 (22.80)18.2507
2000's146 (44.38)29.6817
2010's71 (21.58)24.3611
2020's11 (3.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.79 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index73.15 (26.88)
Search Engine Supply Index2.30 (0.95)

This Compound (41.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.54%)6.00%
Case Studies4 (1.13%)4.05%
Observational0 (0.00%)0.25%
Other341 (96.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]